Prognostic signature identifies key genes in colorectal cancer, predicting overall survival and treatment outcomes.
Key Points
The 2-gene prognostic signature significantly predicts overall survival in colorectal cancer patients, aiding in personalized treatment decisions.
Incorporating clinical characteristics, the signature effectively forecasts 1-, 2-, and 3-year survival rates using ROC analysis.
Differentially expressed genes were identified through TCGA data, further validated with GEO datasets, highlighting their relevance in colorectal cancer.
HEYL and WNT5A, key genes in the Notch pathway, are linked to prognosis, with HEYL indicating higher risk in CRC patients.